Statistical methods in pharmacoepidemiology: advances and challenges*

Abstract

Get full access to this article

View all access options for this article.

References

Garbe E. , Suissa S. Pharmacoepidemiology. In Ahrens W , Pigeot I , eds. Handbook of Epidemiology. Springer-Verlag, Heidelberg, 2005 : pp 1225-66.

Mehrotra DV , Heyse JF Use of the false discovery rate for evaluating clinical safety data. Statistical Methods in Medical Research 2004; 13(3): 227-38.

Friedman MA , Woodcock J. , Lumpkin MM , Shuren JE , Hass AE , Thompson LJ

The safety of newly approved medicines: do recent market removals mean there is a problem?

JAMA 1999; 281(18):1728-34.

Strom, B. (ed). Pharmacoepidemiology. 4th edn. John Wiley & Sons, Ltd, Chichester, 2005.

Ellwood PM Shattuck lecture - outcomes management: a technology of patient experience [Special Report]. New England Journal of Medicine 1988; 318(23):1550-56.

Relman AS Assessment and accountability: the third revolution in medical care. New England Journal of Medicine 1995; 319(18): 1220-22.

Grodstein F. , Stampfer MJ , Manson JE , et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine 1996; 335(7): 453-61.

Grodstein F. , Manson JE , Colditz GA , Willett WC , Speizer FE , Stampfer MJ A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of Internal Medicine 2000; 133(12): 933-41.

Anderson GL , Limacher M. , Assaf AR , et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial . JAMA 2004; 291(14): 1701-12.

10.

Sin DD , Tu JV Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2001; 164(4): 580-84.

11.

Soriano JB , Vestbo J. , Pride NB , Kiri V. , Maden C. , Maier WC Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. European Respiratory Journal 2002; 20(4): 819-25.

12.

Kiri VA , Pride NB , Soriano JB , Vestbo J. Inhaled corticosteroids in chronic obstructive disease: Results from two observational designs free of immortal time bias. Am J Respir Crit Care Med 2005; 172(4): 460-464.

13.

Calverley PM , Anderson JA , Celli B. , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine 2007; 356(8): 775-89.

14.

Bombardier C. , Laine L. , Reicin A. , et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine 2000; 343(21): 1520-28, 2.

15.

Ray WA , Stein CM , Daugherty JR , Hall K. , Arbogast PG , Griffin MR COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360(9339): 1071-73.

16.

Mamdani M. , Rochon P. , Juurlink DN , et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine 2003; 163(4): 481-86.

17.

Suissa S. , Garbe E. Primer: administrative health databases in observational studies of drug effects-advantages and disadvantages. Nature Clinical Practice Rheumatology 2007; 3(12): 725-32.

18.

Solomon SD , McMurray JJ , Pfeffer MA , et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 2005; 352(11): 1071-80.

19.

Solomon DH , Schneeweiss S. , Glynn RJ , et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068-73.

20.

McGettigan P. , Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296(13): 1633-44.

21.

Andersohn F. , Suissa S. , Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction . Circulation 2006; 113(16): 1950-57.

22.

Horwitz RI , Feinstein AR The problem of "protopathic" bias in case-control studies. American Journal of Medicine 1980; 68(2): 255-58.

23.

Miettinen OS , Caro JJ Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. Journal of Clinical Epidemiology 1989; 42: 325-31.

24.

Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiology and Drug Safety 2007; 16(3): 241-49.

25.

Suissa S. Immortal time bias in pharmacoepidemiology. American Journal of Epidemiology 2008; 167(4): 492-99.

26.

Suissa S. Immeasurable time bias in observational studies of drug effects on mortality . American Journal of Epidemiology 2008; 168(3): 329-35.

27.

Rubin DB Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine 1997; 127(8 Pt 2): 757-63.

28.

Brookhart MA , Rassen JA , Wang PS , Dormuth C. , Mogun H. , Schneeweiss S.

Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?

Medical Care 2007; 45(10 Suppl. 2): S116-S122.

29.

Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clinical Pharmacology & Therapeutics 2007; 82(2): 143-56.